EMPLOYMENT AGREEMENTEmployment Agreement • May 29th, 2024 • Medicus Pharma Ltd. • Pennsylvania
WHEREAS the Company wishes to employ the Executive and the Executive wishes to be employed by the Company pursuant to the terms and conditions of this Agreement.
EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 29th, 2024 • Medicus Pharma Ltd.
This Agreement is made and entered into as of the 29th day of April, 2016 ("Effective Date"), by and between the University of Pittsburgh - Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania, with an office at 200 Gardner Steel Conference Center, Thackeray and O'Hara Streets, Pittsburgh, Pennsylvania 15260 ("University"), and Skinject Inc., with its principal business at 4981 McKnight Road, Suite 101371, Pittsburgh, PA 15237 ("Licensee").
AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENTBusiness Combination Agreement • May 29th, 2024 • Medicus Pharma Ltd.
FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 29th, 2024 • Medicus Pharma Ltd.
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "First Amendment") is made as of February 26, 2020 , by and between the University of Pittsburgh - Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania ("University") and SkinJect Inc. ("Licensee").
EMPLOYMENT AGREEMENTEmployment Agreement • May 29th, 2024 • Medicus Pharma Ltd. • Pennsylvania
WHEREAS the Company wishes to employ the Executive and the Executive wishes to be employed by the Company pursuant to the terms and conditions of this Agreement.
AMENDMENT NO. 2 TO THE AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENTBusiness Combination Agreement • May 29th, 2024 • Medicus Pharma Ltd.
A CLINICAL TRIAL AGREEMENT (the "Agreement") is EFFECTIVE the 3rd day of December 2021 (the "Effective Date") BETWEEN: SkinJect, Inc.Clinical Trial Agreement • May 29th, 2024 • Medicus Pharma Ltd. • New York
AMENDED AND RESTATED BUSINESS COMBINATION AGREEMENTBusiness Combination Agreement • May 29th, 2024 • Medicus Pharma Ltd. • Ontario
WHEREAS, subject to the terms and conditions hereof, the Purchaser wishes to acquire the businesses of Skinject pursuant to the Business Combination (as hereinafter defined) whereby, upon the completion of the Business Combination in the manner described herein, Skinject will become a wholly owned subsidiary of the Purchaser; and
MEDICUS PHARMA LTD. 10.00% Unsecured Convertible Notes due 2025 INDENTURE Dated as of May 3, 2024 Odyssey Trust Company, as TrusteeIndenture • May 29th, 2024 • Medicus Pharma Ltd. • Ontario
Pursuant to Section 2.13 of the Indenture, the undersigned registered holder of 10.00% Unsecured Convertible Notes due 2025 hereby notifies you that the undersigned is irrevocably electing to receive [the accrued interest due on the Interest Payment Date which occurs on____________, 20_____] [the accrued and unpaid interest due upon the conversion of the Notes on or about ____________, 20_____] in cash.
SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • May 29th, 2024 • Medicus Pharma Ltd.
This SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this "First Amendment") is made as of April 23, 2024, by and between the University of Pittsburgh - Of the Commonwealth System of Higher Education, a non-profit corporation organized and existing under the laws of the Commonwealth of Pennsylvania ("University") and Medicus Pharma, Ltd. ("Licensee").
